Activery The amorphization specialist
Activery believes that amorphous drugs provide new and innovative routes to final dosage forms with differentiated pharmacokinetics
| Orion files US suit to protect Stalevo drug. |
 |
 |
 |
Finland's Orion files US suit to protect key drugShares Mag 2007 HELSINKI, Dec 8 (Reuters) - Finnish drug firm Orion (ORNBV.HE: Quote, Profile, Research, Stock Buzz) said on Monday it has filed a patent infringement lawsuit in the United States to protect its key drug Stalevo, used for treatment of Parkinson's disease. Indian drug maker Wockhardt Ltd (WCKH.BO: Quote, Profile, Research, Stock Buzz) is seeking to sell a generic version of Stalevo in the United States and has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking to sell the drug, Orion said. "Stalevo is an enhanced levodopa treatment originated by Orion Corporation and marketed in the United States by its exclusive licensee, Novartis (NOVN.VX: Quote, Profile, Research, Stock Buzz)," Orion said in a statement. Orion said by suing to enforce its patent, it is entitled to an automatic stay prohibiting the FDA from approving Wockhardt's application for 30 months -- or until an earlier court decision adverse to Orion's patent in the patent infringement lawsuit. "As such, the realization of generic competition is neither certain nor imminent," Orion said, adding it would vigorously defend the intellectual property rights covering Stalevo. |
Pharma Notes
- New study on Inhaled Drug Delivery Market
- Particles that deliver larger and more effective doses of drugs to cancers
- The global protein therapeutics market will be worth $77bn by 2011 with biogenerics playing an increasingly important rol
- A federal jury in Texas Monday upheld the patent on Johnson & Johnson's arthritis treatment Remicade and ordered Abbott Laboratories to pay its rival $1.67 billion for infringing on the patent
- Transdermal delivery represents an attractive alternative to oral delivery of drugs and is poised to provide an alternative to hypodermic injection tool
Differentiated Generics
- Teva may lose patent challenge
- Labopharm receives notice of ANDA submission with paragraph IV certification for generic of Ryzolt
- Depomed (DEPO) Receives Paragraph IV Notice from Lupin Limited Over Patent Filing for Generic Glumetza Tablets
- The rate and number of successful Paragraph IV challenges is reducing the average effective patent life for innovator drugs
- Teva Sues Mylan Over Multiple Sclerosis Drug COPAXONE
Nanoparticles world
- Nanoparticle created to attack cardiovascular plaque
- Nanoparticle lung threat blocked
- Newly-developed nanoparticle to build therapies for treating individuals with cardiovascular disease.
- Nanoparticle Processing in the Solid State Dramatically Increases the Cell Membrane Permeation of a Cholesterol-Lowering Drug, Probucol
- Erectile dysfunction could be treated by a nanoparticle formulation applied directly to the penis